Terms: = Liver cancer AND FAT1, CDHF7, 2195, ME5, hFat1, CDHR8 AND Treatment
5 results:
1. Effect of Chinese Medicines combined with transarterial chemoembolization on primary hepatic carcinoma: A systematic review and meta-analysis.
Xu J; Shan Y; Zhang C; Hong Z; Qiu Y
Medicine (Baltimore); 2023 Jun; 102(26):e34165. PubMed ID: 37390274
[TBL] [Abstract] [Full Text] [Related]
2. Early Recurrence in Resected Gallbladder Carcinoma: Clinical Impact and Its Preoperative Predictive Score.
Shimizu Y; Ashida R; Sugiura T; Okamura Y; Ohgi K; Yamada M; Otsuka S; Aramaki T; Notsu A; Uesaka K
Ann Surg Oncol; 2022 Sep; 29(9):5447-5457. PubMed ID: 35666409
[TBL] [Abstract] [Full Text] [Related]
3. The combination of camrelizumab and apatinib obtained ongoing partial remission for a patient with osimertinib-resistant non-small cell lung cancer: case report.
Cong X; Chen J; Zheng W
Ann Palliat Med; 2021 Mar; 10(3):3469-3474. PubMed ID: 33040541
[TBL] [Abstract] [Full Text] [Related]
4. Amelioration of non-alcoholic fatty liver disease with NPC1L1-targeted IgY or n-3 polyunsaturated fatty acids in mice.
Bae JS; Park JM; Lee J; Oh BC; Jang SH; Lee YB; Han YM; Ock CY; Cha JY; Hahm KB
Metabolism; 2017 Jan; 66():32-44. PubMed ID: 27923447
[TBL] [Abstract] [Full Text] [Related]
5. Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2.
Lim K; Han C; Dai Y; Shen M; Wu T
Mol Cancer Ther; 2009 Nov; 8(11):3046-55. PubMed ID: 19887546
[TBL] [Abstract] [Full Text] [Related]
